| Literature DB >> 32547124 |
Saeed Khoshnood1,2, Mohammad Savari1,2, Effat Abbasi Montazeri1,2, Ahmad Farajzadeh Sheikh1,2.
Abstract
INTRODUCTION: Acinetobacter baumannii is an opportunistic pathogen responsible for nosocomial infections. The emergence of colistin-resistant A. baumannii is a significant threat to public health. The aim of this study was to investigate the molecular characterization and genotyping of clinical A. baumannii isolates in Southwestern Iran.Entities:
Keywords: Acinetobacter baumannii; MLST; clonal complex; colistin; drug resistance
Year: 2020 PMID: 32547124 PMCID: PMC7266307 DOI: 10.2147/IDR.S253440
Source DB: PubMed Journal: Infect Drug Resist ISSN: 1178-6973 Impact factor: 4.003
Primers Used for the Amplification of Genes
| Target Genes | Sequence (5/–3/) | Amplicon Size (Base Pairs) | References |
|---|---|---|---|
| F:ATGCCTGAGATACAAATTAT | 1449 | ||
| F:GTTAAAGGCGACGTAGACG | 578 | ||
| F:CATCTTCTATTTCGGTCCC | 168 | ||
| F:ATGAATGTCATTATAAAAGC | 925 | ||
| F:AGTCCGTTTGTTCTTGTGGC | 320 | ||
| F:CAAGTGTGTTGGTCGCAGTT | 715 | ||
| F:ACTGGACATGTTGCACTCTTGT | 757 | ||
| F:TCGGGACTTCATAAAAGTGCAT | 722 | ||
| 16S_rRNA | F:CAGCTCGTGTCGTGAGATGT | 150 | |
| Group1ompAF306 | GATGGCGTAAATCGTGGTA | 355 | |
| Group1csuEF | CTTTAGCAAACATGACCTACC | 702 | |
| Gp1OXA66F89 | GCGCTTCAAAATCTGATGTA | 559 | |
| Group2ompAF378 | GACCTTTCTTATCACAACGA | 343 | |
| Group2csuEF | GGCGAACATGACCTATTT | 580 | |
| Gp2OXA69F169 | CATCAAGGTCAAACTCAA | 162 |
Antibiotic Susceptibility Pattern of A. baumannii Isolates
| Antibiotic | LEV | CTZ | CFP | PIP | TGC | AMP/S | COL | CTX | SXT | AMK | CIP | IMI | MER | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Susceptibility pattern | 65 | 70 | 70 | 68 | 32 | 55 | 2 | 70 | 67 | 59 | 65 | 50 | 52 | |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 3 | 0 | ||
| 5 | 0 | 0 | 2 | 38 | 15 | 68 | 0 | 3 | 9 | 5 | 17 | 18 | ||
| Interpretive categories and MIC breakpoints (µg/mL) | ≥8 | ≥32 | ≥32 | ≥128 | ≥8 | ≥32/16 | ≥4 | ≥64 | ≥4/76 | 64 | ≥4 | ≥8 | ≥8 | |
| 4 | 16 | 16 | 32–64 | – | 16/8 | – | 16–32 | – | 32 | 2 | 4 | 4 | ||
| ≤2 | ≤8 | ≤8 | ≤16 | <8 | ≤8/4 | ≤2 | ≤8 | ≤ 2/38 | 16 | ≤1 | ≤2 | ≤2 | ||
Abbreviations: LEV, levofloxacin; CTZ, ceftazidime; CFP, cefepime; PIP, piperacillin; TGC, tigecycline; Amp/S, ampicillin/sulbactam; COL, colistin; CTX, cefotaxime; SXT, trimethoprim-sulphamethoxazole; AMK, amikacin; CIP, ciprofloxacin; IMI, imipenem; MEM, meropenem; R, resistant; I, intermediate; S, susceptible.
Characteristics of A. baumannii Strains
| Strain ID | Biofilm | Phe | MIC | Biofilm Genes | IC | MLST | |||
|---|---|---|---|---|---|---|---|---|---|
| MER | TGC | COL | |||||||
| Ab 1 | S | XDR | 16 | 64 | 0.5 | bap, ompA, csuE | G1 | – | – |
| Ab 2 | S | MDR | 0.25 | 16 | 0.5 | bap, ompA, csuE, blaPER-1 | G1 | – | – |
| Ab 3 | S | XDR | 64 | 2 | 0.5 | bap, ompA, csuE | G2 | – | – |
| Ab 4 | S | XDR | 128 | 8 | 32 | bap, ompA, csuE, blaPER-1 | G2 | 387 | – |
| Ab 5 | W | MDR | 16 | 16 | 0.25 | bap,ompA | G1 | – | – |
| Ab 6 | S | MDR | 0.5 | 4 | 0.25 | bap, ompA, csuE, blaPER-1 | G2 | ||
| Ab 7 | S | MDR | 128 | 0.25 | 1 | bap, ompA, csuE | G15 | 138 | 92 |
| Ab 8 | S | MDR | 16 | 32 | 0.5 | bap, ompA, csuE | G1 | – | – |
| Ab 9 | S | MDR | 8 | 1 | 0.5 | bap, ompA, csuE, blaPER-1 | G1 | – | – |
| Ab 10 | N | XDR | 32 | 0.5 | 0.25 | ompA, csuE, blaPER-1 | G10 | – | – |
| Ab 11 | M | MDR | 0.5 | 64 | 0.125 | bap, ompA, csuE | G1 | – | – |
| Ab 12 | S | MDR | 128 | 0.25 | 0.25 | bap, ompA, csuE, blaPER-1 | G1 | – | – |
| Ab 13 | S | MDR | 0.25 | 2 | 0.5 | bap, ompA, csuE | G1 | – | – |
| Ab 14 | S | MDR | 16 | 32 | 0.5 | bap, ompA | G4 | – | – |
| Ab 15 | S | MDR | 256 | 0.25 | 0.25 | bap, ompA | G10 | – | – |
| Ab 16 | N | MDR | 256 | 1 | 0.25 | ompA, csuE, blaPER-1 | G1 | ||
| Ab 17 | S | MDR | 32 | 0.5 | 0.25 | bap, ompA, csuE | G2 | – | – |
| Ab 18 | S | MDR | 0.5 | 32 | 0.125 | bap, ompA, csuE | G1 | – | – |
| Ab 19 | M | MDR | 0.5 | 0.25 | 0.25 | bap, ompA, csuE | G10 | – | – |
| Ab 20 | S | MDR | 32 | 16 | 0.5 | bap, ompA, csuE | G1 | – | – |
| Ab 21 | S | MDR | 16 | 1 | 0.25 | bap, ompA | G1 | – | – |
| Ab 22 | S | MDR | 128 | 0.5 | 1 | bap, ompA, csuE, blaPER-1 | G1 | 118 | 92 |
| Ab 23 | S | MDR | 256 | 16 | 0.25 | bap, ompA, csuE, blaPER-1 | G15 | – | – |
| Ab 24 | N | MDR | 16 | 2 | 0.25 | ompA, csuE | G 1 | – | – |
| Ab 25 | S | MDR | 2 | 8 | 0.125 | bap, ompA, csuE | G 4 | – | – |
| Ab 26 | S | MDR | 16 | 4 | 2 | bap, ompA | G 1 | 421 | 92 |
| Ab 27 | S | XDR | 16 | 32 | 0.25 | bap, ompA, csuE, blaPER-1 | G 10 | – | – |
| Ab 28 | W | MDR | 64 | 0.5 | 0.25 | ompA, csuE | G 1 | – | – |
| Ab 29 | S | MDR | 0.25 | 8 | 0.25 | bap, ompA, csuE, blaPER-1 | G 1 | – | – |
| Ab 30 | S | MDR | 0.5 | 8 | 0.5 | bap, ompA, csuE | G 2 | – | – |
| Ab 31 | S | MDR | 8 | 16 | 0.25 | bap, ompA | G 1 | – | – |
| Ab 32 | S | MDR | 128 | 1 | 1 | bap, ompA, csuE | G 4 | 216 | 405 |
| Ab 33 | S | MDR | 0.5 | 0.25 | 0.125 | bap, ompA, csuE | G 7 | – | – |
| Ab 34 | M | MDR | 32 | 32 | 0.25 | bap,ompA, csuE, blaPER-1 | G 10 | – | – |
| Ab 35 | S | MDR | 0.5 | 1 | 0.25 | bap, ompA | G 1 | – | – |
| Ab 36 | M | MDR | 16 | 0.5 | 0.5 | bap,ompA, csuE | G 15 | – | – |
| Ab 37 | N | MDR | 256 | 8 | 2 | ompA, csuE, blaPER-1 | G 1 | 735 | 92 |
| Ab 38 | M | MDR | 0.5 | 32 | 0.5 | bap, ompA, csuE, blaPER-1 | G 2 | – | – |
| Ab 39 | S | MDR | 0.25 | 4 | 0.25 | bap, ompA, csuE | G 10 | – | – |
| Ab 40 | S | MDR | 16 | 1 | 0.25 | bap, ompA, csuE | G 1 | – | – |
| Ab 41 | S | XDR | 64 | 16 | 8 | bap, ompA, blaPER-1 | G 1 | 1812 | – |
| Ab 42 | S | MDR | 16 | 0.5 | 0.25 | bap, ompA, csuE | G 1 | – | – |
| Ab 43 | S | MDR | 2 | 4 | 0.25 | bap, ompA, csuE | G10 | – | – |
| Ab 44 | S | MDR | 16 | 4 | 0.5 | bap, ompA, csuE | G 1 | – | – |
| Ab 45 | M | MDR | 128 | 16 | 0.25 | bap,ompA, blaPER-1 | G15 | – | – |
| Ab 46 | S | MDR | 16 | 0.5 | 0.5 | bap, ompA, csuE | G4 | – | – |
| Ab 47 | S | MDR | 2 | 32 | 0.25 | bap, ompA, csuE | G 1 | – | – |
| Ab 48 | S | MDR | 16 | 1 | 0.5 | bap, ompA, csuE, blaPER-1 | G1 | – | – |
| Ab 49 | S | MDR | 16 | 8 | 1 | bap, ompA | G2 | 133 | 225 |
| Ab 50 | S | MDR | 32 | 8 | 0.25 | bap, ompA, csuE | G1 | – | – |
| Ab 51 | S | XDR | 16 | 0.25 | 0.5 | bap, ompA, csuE | G1 | – | – |
| Ab 52 | M | MDR | 16 | 2 | 0.25 | bap,ompA | G7 | – | – |
| Ab 53 | S | XDR | 0.5 | 16 | 0.25 | bap, ompA, csuE | G10 | – | – |
| Ab 54 | S | MDR | 16 | 8 | 0.5 | bap, ompA, csuE, blaPER-1 | G1 | – | – |
| Ab 55 | S | MDR | 64 | 0.5 | 0.5 | bap, ompA, csuE | G 1 | – | – |
| Ab 56 | S | MDR | 16 | 4 | 0.25 | bap, ompA, csuE, blaPER-1 | G 1 | – | – |
| Ab 57 | S | MDR | 32 | 16 | 0.5 | bap, ompA, csuE | G 4 | – | – |
| Ab 58 | S | MDR | 16 | 8 | 0.25 | bap, ompA, csuE | G1 | – | – |
| Ab 59 | S | MDR | 0.25 | 0.5 | 0.5 | bap, ompA, csuE, blaPER-1 | G4 | – | – |
| Ab 60 | S | MDR | 16 | 1 | 0.25 | bap, ompA | G1 | – | – |
| Ab 61 | S | MDR | 128 | 0.5 | 1 | bap, ompA, csuE | G7 | 848 | 92 |
| Ab62 | S | MDR | 16 | 8 | 0.25 | bap, ompA, csuE | G15 | – | – |
| Ab 63 | S | MDR | 32 | 1 | 0.5 | bap, ompA, csuE | G10 | – | – |
| Ab 64 | N | MDR | 16 | 2 | 0.25 | ompA, csuE, blaPER-1 | G2 | – | – |
| Ab 65 | S | MDR | 125 | 32 | 0.25 | bap, ompA, csuE | G1 | – | – |
| Ab 66 | S | XDR | 16 | 32 | 0.5 | bap, ompA | G1 | – | – |
| Ab 67 | S | MDR | 16 | 64 | 0.25 | bap, ompA, csuE | G10 | – | – |
| Ab 68 | S | MDR | 0.25 | 0.5 | 0.25 | bap, ompA, blaPER-1 | G1 | – | – |
| Ab 69 | W | MDR | 16 | 2 | 1 | bap,ompA, csuE | G10 | 118 | 92 |
| Ab 70 | S | MDR | 128 | 16 | 0.25 | bap, ompA, csuE | G1 | – | – |
Abbreviations: Phe, phenotype; MDR, multidrug-resistant; XDR, extensively drug-resistant; M, medium; N, non-biofilm-forming; W, weak; S, strong; MIC, minimum inhibitory concentration; MER, meropenem; TGC, tigecycline; COL, colistin; IC, international clonal lineage.
The Relationship Between Biofilm Formation and Related Genes in A. baumannii Strains with MDR and XDR Phenotypes
| Biofilm Intensity (No.) | bap No (%) | ompA No (%) | csuE No (%) | bla-PER1 No (%) | ||||
|---|---|---|---|---|---|---|---|---|
| Positive | Negative | Positive | Negative | Positive | Negative | Positive | Negative | |
| Strong (55) | 55 (100) | 0 (0) | 55(100) | 0 (0) | 44 (80) | 11(20) | 15(27.27) | 40(72.73) |
| Moderate (7) | 7 (100) | 0 (0) | 7 (100) | 0 (0) | 5(71.4) | 2(28.57) | 3 (42.85) | 4 (57.14) |
| Weak (3) | 2 (66.6) | 1 (33.3) | 3(100) | 0 (0) | 2 (66.6) | 1 (33.3) | 0 (0) | 3 (100) |
| Non- Biofilm forming (5) | 0 (0) | 5 (100) | 5(100) | 0 (0) | 5 (100) | 0 (0) | 4 (80) | 1(20) |
| Total | 64(91.4) | 6 (8.6) | 70(100) | 0 (0) | 56 (80) | 14 (20) | 22 (31.42) | 48(68.58) |
| P value | <0.001 | – | 0.552 | 0.053 | ||||
Figure 1Gene expression comparison of pmrA and pmrB in colistin-resistant (Ab 4, Ab41) and susceptible isolates (Ab49, Ab61, Ab69, Ab22, Ab26, Ab7, Ab32, Ab37) and A. baumannii ATCC 19606.
The Relation Between Biofilm Intensity with Antibiotic Susceptibility, Phenotype, and IC
| Biofilm Intensity (No.) | Antibiotic N (%) | Phenotype N (%) | IC | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Colistin | Meropenem | Tigecycline | MDR | XDR | I | II | IV | ||||
| R | S | R | S | R | S | ||||||
| Strong (55) | 2 (3.6) | 53 (96.4) | 40 (72.72) | 15 (27.28) | 26 (47.27) | 29(52.73) | 47 (85.45) | 8(14.54) | 6 | 31 | 18 |
| Moderate(7) | 0 (0) | 7 (100) | 4 (57.15) | 3 (42.85) | 4 (57.14) | 3 (42.86) | 7 (100) | 0(0) | 1 | 1 | 5 |
| Weak(3) | 0 (0) | 3(100) | 3 (100) | 0 (0) | 1(33.33) | 2 (66.67) | 3 (100) | 0(0) | 0 | 2 | 1 |
| Non- Biofilm | 0 (0) | 5 (100) | 5(100) | 0 (0) | 1(20) | 4(80) | 4 (80) | 1(20) | 1 | 3 | 1 |
| p-value | 1 | 0.342 | 0.608 | 0.662 | |||||||
| Total | 2 (2.8) | 68 (97.1) | 52 | 18 | 32 | 38 | 61(87.1) | 9 (12.8) | 8 | 37 | 25 |